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The natural history of chronic hepatitis B infection
GKK Lau, CL Lai, PC Wu
Chronic hepatitis B infection is a global health problem that affects about 300 million people. Of these,
75% are Chinese. Most Chinese who become chronic carriers, contract the virus during the perinatal
period. The natural history of these chronic hepatitis B carriers includes an initial immune tolerance
phase, followed by immune clearance and an inactive hepatitis B non-replicative phase with the develop-
ment of cirrhosis that may be complicated by hepatocellular carcinoma. The classification of hepato-
cellular carcinoma has recently been revised. Based on immunohistochemical studies, it has been found
that patients with hepatocellular carcinoma and biliary markers have a poorer survival than patients
with hepatocellular carcinoma but who have negative biliary markers. Sometimes, a fourth phase, a
hepatitis B envelope-negative hepatitis B virus replicative phase, reflecting the emergence of a pre-core
mutant strain, may follow. Our improved understanding of the natural history of chronic hepatitis B
infection has led to more effective approaches towards the control of this viral infection and its sequelae.
Most importantly, immunisation against hepatitis B virus in the perinatal setting has been shown to
prevent chronic infection.
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Introduction
Hepatitis B virus (HBV) infection is one of the most
common viral infections in humans. It has been
estimated that chronic hepatitis B infection affects ap-
proximately 300 million individuals, or 5% of the
world’s population.1 This is of particular concern in
the Asia-Pacific region, where chronic HBV infection
is prevalent, with a carrier rate of approximately 10%.
Of the chronic HBV carriers, between 25% to 40%
will eventually die from liver disease (cirrhosis with
or without hepatocellular carcinoma [HCC]); the death
rate being 50% for male carriers and 15% for female
carriers.2 The natural history of chronic HBV infec-
tion in Chinese is characterised by an initial active vi-
ral replicative state with minimal liver damage
(immune tolerance phase), followed by an active im-
mune clearance phase with chronic active hepatitis and
later an inactive HBV non-replicative phase with the
development of cirrhosis that may be complicated by
HCC.3 In addition, some patients enter a stage that is
characterised by viraemia and chronic active hepatitis
in the absence of hepatitis B envelope (HBe) anti-
genaemia.4
Establishment of chronic hepatitis B virus
infection
The age at infection is the single most important
factor affecting chronic HBV carriage. There is an
inverse relationship between the risk of chronicity
of HBV infection and age. The risk is 80% to 90%
for infections that occur before the age of one year,
20% to 50% for infections in early childhood, and
only 1% to 2% for infections in adults.5 Unlike
Caucasians who acquire HBV infection in adult-
hood, Chinese usually acquire the infection perinatally.6
The high frequency of maternal transmission among
Chinese is related to the prevalence of carrier mothers
with HBe antigen (HBeAg), a marker of HBV repli-
cation and infectivity. The prevalence of HBeAg
positivity is estimated to be 40%, 15%, and 10% among
Chinese, African, and Caucasian carrier mothers, re-
spectively.7-9 Because of the infectivity of the carrier
mothers and the possibly interfering role of HBeAg,
which can cross the placenta and induce HBV-specific
host tolerance, HBV infection becomes chronic in
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approximately 90% of infants born to HBeAg-
positive mothers.10 The highly infectious maternal
blood may infect the newborn through placental leak-
age during labour, or through the disrupted mucous
membrane and skin of the newborn in the birth canal.
In approximately 3% of these newborns, HBV infec-
tion is believed to occur in utero, and transplacental
leakage of the maternal blood may be the most likely
route of intrauterine infection. Once the infection be-
comes chronic, hepatitis B surface antigen (HBsAg)
carriage is sustained, with an overall incidence of loss
of HBsAg in 0.6% of child carriers per year. This low
percentage of HBsAg clearance persists in adult
carriers.11 Seroconversion to hepatitis B surface
antibody (anti-HBs) occurs even less frequently. In
such instances, serum HBV DNA is cleared and is
undetectable even by polymerase chain reaction (PCR)
assay. However, HBV DNA may still be present in low
levels in the liver.
The different phases of hepatitis B virus
infection
In Hong Kong Chinese, most chronic HBV carriers
acquire the infection during the perinatal period. There
are generally three phases in the evolution of chronic
HBV infection: (1) the immune tolerance phase; (2)
the immune clearance phase; and (3) the residual non-
replicative integrated HBV phase. Sometimes, a fourth
phase with HBeAg-negative HBV replication, reflect-
ing the emergence of a pre-core mutant strain, may
follow (Fig 1).
The immune tolerance phase
The immune tolerance phase is characterised by a lack
of clinical symptoms. The livers in these young HBV
carriers, however, usually show some abnormalities
histologically, albeit mild and non-specific ones. This
is supported by the frequent finding of a slightly ele-
vated serum alanine aminotransferase (ALT) level.12
This liver pathology is also observed in asymptomatic
young adults. The disease activity is low during this
phase despite active HBV replication—high serum
HBV DNA and HBeAg levels and abundant hepatitis
B core antigen (HBcAg) in hepatocyte nuclei. The short
term prognosis during this period is good.
The exact mechanism that leads to the development
of immune tolerance is not known. Experiments in mice
suggest that the transplacental transfer of maternal
HBeAg may induce a specific unresponsiveness of helper
T cells to HBeAg in neonates born to HBeAg-positive
carrier mothers.13 As HBeAg and HBcAg are highly
cross-reactive at the T-cell level, a reduced helper T-
cell response to HBeAg would also impair the T-cell
response to HBcAg, resulting in an ineffective cyto-
toxic T-cell lysis of infected hepatocytes.14 This hy-
pothesis is supported by the lack of a proliferative
response and increase in the interleukin-2 (IL-2) receptors
of peripheral blood mononuclear cells after stimulation
by recombinant HBcAg.15 Unresponsiveness can be re-
stored by depleting suppressor T cells, which supports a
defect in helper T cells as being the problem.16 Immune
tolerance accounts for the lack of symptoms and inactive
liver disease despite the high levels of HBV replication.
Fig 1. Natural history of chronic hepatitis B virus infection
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The immune clearance phase
The immune clearance phase marks the transition from
the replicative immune tolerance phase to the non-
replicative phase. It is characterised by seroconversion
from HBeAg to anti-HBe positivity. With the develop-
ment of anti-HBe, viral replication usually ceases and
the liver disease becomes inactive. However, subse-
quent reactivation of HBV replication with reappear-
ance of HBV DNA and HBeAg in the serum and a
recrudescence of the underlying liver disease may de-
velop. This change is well documented in carriers when
immunosuppressive therapy is withdrawn,17 but the
spontaneous reactivation of hepatitis B infection has
also been described.18 A spontaneous clearance of
HBeAg is rarely seen during the first two decades of
life. The rate of clearance of HBeAg increases with
the age of the patient. The cumulative probabilities of
spontaneous sustained clearance of HBeAg at the end
of one and five years, post-infection, are estimated to
be 2% and 12% for patients aged below 20 years, 8%
and 32% for patients aged between 21 to 40 years, and
16% and 48% for those older than 40 years.19 The es-
timated annual rate of sustained clearance of HBeAg
is only 2.8% for patients below the age of 20 years.
This low rate of spontaneous clearance of HBeAg, par-
ticularly during the first two decades of life, helps to
explain why 50% of Chinese HBV adult carriers have
serological markers of HBV replication and accounts
for the high frequency of maternal to infant transmis-
sion in the Chinese. It is uncertain if the spontaneous
clearance of HBeAg occurs as a result of breakdown
in immune tolerance with age, gradual decrease in
production of tolerogenic HBeAg secondary to the
development of pre-core mutants, or the appearance
of new, non-tolerant HBcAg epitopes through the
selection of mutants after numerous cycles of HBV
replication.
Disease activity, however, increases during the
transition phase. Clinically, a previously asymptomatic
carrier may have bouts of symptoms and signs sug-
gestive of acute hepatitis, i.e. acute exacerbations of
chronic HBV infection. Expression of histocompati-
bility antigen class I antigen on the hepatocyte in-
creases, thus favouring the attack on HBV-infected
hepatocytes by cytotoxic T lymphocytes.20 The viral
antigen responsible for the immunopathogenesis is
likely to be HBcAg, because early in the course of
acute exacerbations, specific cellular immune responses
to HBcAg increase, as revealed by amplified T-cell
proliferative responses to HBcAg.21 This is further sup-
ported by an increase in cytoplasmic HBcAg expres-
sion in chronic active hepatitis (CAH).22 In contrast,
the nuclear expression of HBcAg and the nuclear and
cytoplasmic expression of HBeAg show a trend from
the carrier state and chronic persistent hepatitis (CPH),
through CAH, to cirrhosis, with or without HCC (Fig
2). The presence of cytoplasmic HBcAg has also been
found to correlate significantly with lobular activity,
portal inflammation, and hepatitic activity. During this
period, therefore, the liver suffers continuous and re-
peated bouts of damage, documented by elevated se-
rum ALT, which increases to high levels during acute
exacerbations. The acute exacerbation is usually self-
limiting, although a small proportion of patients may
suffer liver failure during the acute exacerbation, es-
pecially those who have cirrhosis. Lobular hepatitis
becomes active, and the histological changes may
mimic acute hepatitis.23 There are differences, in terms
of immunohistochemical staining, between lobular
hepatitis and acute hepatitis. Hepatitis B surface anti-
gen can be demonstrated in hepatocytes in lobular
hepatitis but not in acute hepatitis B. In addition,
HBcAg is frequently seen in the cytoplasm.24
The histological picture varies from CPH to CPH
with lobular hepatitis, to CAH, and active cirrhosis.
However, the histological findings that lead to the diag-
nosis of CAH and CPH with lobular hepatitis are in-
terchangeable. It is not unusual for an HBeAg-
positive HBsAg carrier to have CPH with prominent
lobular hepatitis or CAH during an acute exacerba-
tion, but after recovering from the exacerbation, the
liver may show a typical histological picture of CPH.
If cirrhosis does not supervene, after seroconversion
to anti-HBe, the liver may show only minimal histo-
logical abnormalities or may even appear normal.25
After a series of acute exacerbations, the liver shows
cirrhotic changes in about 40% of those with severe
CAH. The incidence of cirrhosis has been shown to be
Fig 2. Expression of hepatitis B core antigen in a
patient with chronic active hepatitis. Hepatitis B
core antigen (brown) shows prominent nuclear and
cytoplasmic staining; Hepatitis B envelope antigen
(pink) is largely confined to the nuclei (x 350)
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approximately 2% per year.26 Those with persistent
HBcAg in the liver and higher serum HBV DNA are
more likely to have aggressive forms of the disease,
which often progress to cirrhosis.25
Residual hepatitis B virus integrated phase
During this phase, the active replication of HBV ceases.
The HBV DNA often has become integrated into the
host’s chromosomal genome, but HBsAg is continu-
ously being produced by the liver cells that contain
these integrated HBV genome.26 Due to the absence
of active HBV replication or very low viral replication
in the liver, the hepatocytes are spared from attack by
the immune cells. The outcome of chronic HBV in-
fection appears to be dependent on the severity of liver
injury before HBV replication ultimately ceases. Thus,
patients with prolonged and fluctuating transition from
the replicative to non-replicative phase (with recurrent
exacerbations) are more likely to develop cirrhosis
and HCC.27,28 Recurrent exacerbations are more
frequent in male patients and this may explain why
male carriers of HBV are more likely to develop HBV-
related cirrhosis and HCC, compared with female
carriers. The residual underlying pathology of the liver
already present at the time when HBV replication
ceases, is crucial for determining the outcome of the
HBsAg carrier.29 If cirrhosis has not developed, the
previously active hepatitis will regress to an inactive
state with a well-preserved liver architecture remaining.
On the other hand, if cirrhotic changes are present at
the time of HBeAg seroconversion, the cirrhosis will
remain and progress, although slowly and usually
asymptomatically. In those patients with cirrhosis and
active HBV replication, the cirrhotic process will re-
main active. The prognosis is then poor, and hepatic
failure or other complications of cirrhosis may appear
relatively quickly. A significant proportion of HBsAg
carriers will develop HCC,30 especially those with
cirrhosis.
Hepatitis B envelope antigen-negative replicative
phase
The HBeAg-negative replicative phase is characterised
by elevated serum aminotransferase in the absence of
HBeAg in serum. The serum anti-HBe may be either
positive or negative.31 These changes are accompanied
by the emergence of an HBV pre-core mutant. The
predominant mutation involves a G to A change at
nucleotide 1896 in the pre-core region; the mutant is
able to form viral particles, but not HBeAg.31 As a re-
sult, viral replication can remain high in the absence
of serum HBeAg. It is not known if this mutation di-
rectly affects viral pathogenicity. During this phase,
the liver histology shows aggressive liver disease.
Chronic persistent hepatitis is seen in a few patients
while changes of severe CAH with active necro-
inflammation are seen in more than 50% of cases.
Ground-glass hepatocytes with abundant cytoplasmic
HBsAg are frequent and HBcAg is detected both in
the nucleus and cytoplasm of hepatocytes. The amount
of cytoplasmic HBcAg is sometimes impressive, indi-
cating abundant formation and retention in the cyto-
plasm.32 A membranous localisation of HBcAg has also
been observed, supporting the view that it represents a
target of immune attack by cytotoxic T lymphocytes.33
The consequences of chronic hepatitis B virus
infection
Patients with chronic HBV infections may ultimately
suffer from decompensated cirrhosis and die from
its complications (portal hypertension with variceal
bleeding, spontaneous bacterial peritonitis, and hepatic
failure). Many others, however, die of other concurrent
diseases unrelated to their chronic viral infections or
liver disease. In addition, it has been estimated that
the relative risk of HCC developing in chronic HBV
carriers is 100 times higher than that in matched
controls.34 The aetiological role of HBV in HCC is
further supported by the increased prevalence of tissue
HBsAg in cases of HCC, with or without cirrhosis35,36
and the association between tissue HBsAg and liver
cell dysplasia.37 The mechanisms of carcinogenesis
are not clear and appear complex. Hepatitis B virus-
induced hepatocarcinogenesis has been ascribed to a
variety of causes, including the insertional deregulation
of cellular growth control genes by the integrated
viral DNA sequences that are commonly found in
HCC; the random deregulation of cellular growth
control genes by chromosomal and genetic lesions
caused by increased hepatocellular turnover and the
mutagenic environment of the inflamed liver; and
the transcriptional deregulation of cellular growth
control genes by the viral transactivating protein (the
X protein) that may itself be deregulated secondary
to structural changes in the viral genome that occur
during integration.
Integrated HBV DNA can be detected in tumour
tissue from most HBsAg-positive patients with HCC.
As integration appears to occur at random sites in the
host genome, it may not play a key role in hepato-
carcinogenesis.38 On the other hand, the p53 tumour
suppressor gene has been found in about 30% of
human HCCs. Somatic mutations at codon 249 of
the p53 gene are observed more often in countries
where there is dietary contamination by aflatoxin,
a mycotoxin capable of inducing HCC in animals.
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Aflatoxin B1 is a mutagen that induces G to T base
substitutions and shows a preference for p53 codon
249 in assays in vitro.39 The role of this mutation in
human HCC is still uncertain.
Previously, primary liver cancer has been classi-
fied into HCC and cholangiocarcinoma with a rare
combined type of hepatocellular-cholangiocellular
carcinoma. Hepatocellular carcinoma has always been
considered a single disease based on the assumption
that it originates from a single cell type, the hepato-
cyte or ‘hepatocyte precursor cell.’ Cholangio-
carcinoma is believed to originate from biliary epithe-
lial cells. The diverse clinical and pathobiological
behaviours seen, however, suggest that HCC is a
heterogenous disease. Recent evidence from experi-
mental chemical carcinogenesis models of HCC have
suggested that ‘oval cells,’ which possess both hepato-
cyte and biliary cell markers, are closely related to
pleuripotent stem cells and have dual potential to
differentiate into either hepatocytes or biliary epithe-
lial cells. Can HCC be reclassified, based on the pres-
ence or absence of biliary markers and would such
reclassification of HCC provide better clinical and
pathobiological information?40 Liver tissue from 290
Chinese patients with HCC were studied; HBsAg was
positive in 86.1% and histological evidence of cirrho-
sis was identified in 122/151 (80.8%) tissue blocks
where adequate liver tissue was available for assess-
ment. The liver specimens included 201 needle biop-
sies, 73 surgical resection specimens, and 16 specimens
from autopsies. Using immunohistochemistry tech-
niques, the expression of hepatocytic differentiation
markers (HEP-PAR reactive antigen) and biliary dif-
ferentiation markers (AE1-AE3, CK19) were studied.
It was found that no patient with HCC with biliary
markers survived for more than 27 weeks, compared
with a 22.6% survival rate for patients with HCC nega-
tive for biliary markers.
In the course of chronic HBsAg carriage, HCC
can emerge at any time, even as early as three years
of age. The cancer is more likely to develop in
maternally-transmitted HBsAg carriers, usually
becoming apparent after the age of 40 years.
Contrary to previous beliefs, HCC grows relatively
slowly, at least in its early stage, the volume
doubling time being 110 days, on average.41 There
are no symptoms attributable to HCC when the
cancer is small. Symptoms develop only after the
tumour is big.42 The perception of HCC in the past
as a rapidly progressive, fatal malignancy is generally
erroneous. It may take years for a tumour to grow
to a size large enough to cause symptoms.
Conclusion
A better understanding of the natural history of chronic
HBV infection would enable us to treat this infection
more effectively. As most chronic HBV carriers who
are Chinese acquired their HBV infection perinatally,
large scale immunoprophylaxis at birth would be the
most effective preventive measure.43 To date, interferon
is the only agent approved in the West for the treat-
ment of chronic HBV infection. However, the response
to interferon in Chinese is unsatisfactory. This is largely
due to the presence of the immune tolerance phase in
Chinese. Hence, the response to interferon is higher in
those Chinese patients with elevated aminotransferase
levels (i.e. during the immune clearance phase).44
Screening with ultrasound and detecting serum α-
fetoprotein has enabled us to detect early resectable
HCCs. However, it is still uncertain whether these
measures improve the long term survival of patients
with HCC.45 Further studies on the mechanisms of
viral persistence, immunopathogenesis, and hepato-
carcinogenesis will shed more light on this important
viral infection, and eventually yield more practical and
effective means for its control and treatment.
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